This Article Full Text Full Text (PDF) All Versions of this Article: 34/6/e45    most recent 01.STR.0000072275.34976.73v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ESPRIT Search for Related Content PubMed PubMed Citation Articles by ESPRIT, Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Blood Thinners Related Collections Secondary prevention Cerebrovascular disease/stroke Coumarins Intracerebral Hemorrhage Anticoagulants Antiplatelets Transient Ischemic Attacks

(Stroke. 2003;34:e45.)
© 2003 American Heart Association, Inc.

Research Reports

Oral Anticoagulation in Patients After Cerebral Ischemia of Arterial Origin and Risk of Intracranial Hemorrhage

From the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) Study Group.

Correspondence to Ale Algra, MD, Department of Neurology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Room D.01.335, Heidelberglaan 100, 3584 CX Utrecht, Netherlands. E-mail a.algra{at}neuro.azu.nl

Background and Purpose— In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns. Such concerns are corroborated by the results of the Stroke Prevention in Reversible Ischemia Trial (SPIRIT), which was stopped early because of a high incidence of intracranial hemorrhage with a target international normalized ratio (INR) of 3.0 to 4.5. In the ongoing European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an intermediate anticoagulation regimen (INR 2.0 to 3.0) is used.

Methods— We performed an interim analysis of the incidence of intracranial hemorrhage in ESPRIT.

Results— Thus far the overall rate of intracranial hemorrhage is 0.31% (95% CI, 0.18% to 0.52%) per year and 1.21% if all of these were in the anticoagulation group.

Conclusions— We conclude that anticoagulation with achieved INR of 2.0 to 3.0 is reasonably safe in patients with cerebral ischemia of arterial origin.

Key Words: anticoagulants • aspirin • cerebral ischemia • intracerebral hemorrhage

This article has been cited by other articles:

				A L Teixeira Jr, M M Teixeira, F J Carod-Artal, A P Vargas, M Melo, and T A Horan Ischaemic stroke in chagasic patients * Authors' reply J. Neurol. Neurosurg. Psychiatry, March 1, 2004; 75(3): 510 - 510. [Full Text] [PDF]

				N. Paul, C. M. Kosinski, A. C. Gelber, A. S. Saleh, S. D. Stern, M. Crowther, and J. Ginsberg Warfarin Prophylaxis in the Antiphospholipid Antibody Syndrome N. Engl. J. Med., December 25, 2003; 349(26): 2568 - 2570. [Full Text] [PDF]

				ESPRIT ESPRIT: Safety and Efficacy of Oral Anticoagulation--a Rebuttal Stroke, October 1, 2003; 34 (10): e184 - e184. [Full Text] [PDF]